

NCIC CTG Workshop: Future Directions in Clinical/Translational Research in Glioma

Delta Chelsea Hotel, Toronto
Saturday, 27 April 2013

8:00-8:15 Welcome/Introductions/Overview/Goals - W Mason

Glioblastoma Multiforme

- 8:15-9:15 Overview of landscape of molecular biology and potential impact on target selection –D Cahill
- 9:15-9:30 Overview of current state of drug development and potential impact on treatment and design of future trials - W Mason
- 9:30-10:15 Cooperative Group Updates
EORTC - update and plans - W Wick
Alliance - update & plans - E Galanis
COGNO - update & plans - L Hovey
NCIC CTG - update & plans - C O'Callaghan
- 10:15-10:30 Coffee Break
- 10:30-11:00 Promising New Targets and Therapies – W Mason
- 11:00-11:30 Novel Approaches to Clinical Trial Design in GBM - E Galanis
- 11:30-12:00 Biomarker and Correlative Studies: directions and issues - M Hegi
- 12:00-13:00 LUNCH

Anaplastic and Low-Grade Gliomas

- 13:00-14:00 Overview of landscape of molecular biology and potential impact on target selection - D Cahill
- 14:00-14:30 Anaplastic Glioma - Update of current trials
EORTC (26053-22054) "CATNON" – M van den Bent
NCCTG (N0577) "CODEL" – K Jaeckle (or designate)
- 14:30-15:00 Low Grade Gliomas-Update of current trials
EORTC (22033-26033) update - B Baumert
RTOG 9802 & ECOG E3F05 – D Schiff
- 15:00-15:30 Ideas for novel phase II trials in low-grade gliomas - G Cairncross
- 15:30-15:45 Coffee Break

Other Opportunities for Collaboration

- 15:45-16:00 Brain Metastases- D Roberge, C Chung
16:00-16:15 Meningioma - D Roberge, B Baumert

Interactive Panel

- 16:15-16:50 Opportunities for Intergroup Collaboration- G Cairncross, R Stupp, J Buckner, L Hovey, M Hegi
16:50-17:00 Concluding Remarks and Adjourn - W Mason